Key facts
- It has raised $29.9M; the latest was Early Stage VC ($14.2M) in Dec 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, HSG (Hong Kong), CDH Investments, CMB International Capital, Northern Light Venture Capital — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for HemaCell
- ·The full record, as it builds
Funding rounds
No funding rounds for HemaCell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HemaCell
Developer of platelets produced in vitro and related drugs based in Suzhou, Jiangsu. The company focuses on solving the urgent need for platelets in diseases such as cancer, liver disease, critical illness, and hematological diseases, thereby developing innovative drugs for various diseases related to platelet abnormalities, and providing clients with effective treatment plans.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- xuejibio.com/
- Ownership
- Privately Held (backing)
HemaCell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HemaCell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HemaCell in its N-PORT filings yet. We sweep new filings monthly.